Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model

International Journal of Antimicrobial Agents

Volumn 33, Issue 3, 2009, Pages 251-254

  Strukova, Elena N ^a   Smirnova, Maria V ^a   Vostrov, Sergey N ^a   Lubenko, Irene Y ^a   Firsov, Alexander A ^a   Zinner, Stephen H ^b   Portnoy, Yury A ^a,c  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b MOUNT AUBURN HOSPITAL   (United States)

^c P K ANOKHIN INSTITUTE OF NORMAL PHYSIOLOGY   (Russian Federation)

Author keywords

Bacterial killing; Concentration response relationships; Simulated pharmacokinetics

Indexed keywords

LINEZOLID; VANCOMYCIN;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; COLONY FORMING UNIT; IN VITRO STUDY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; COLONY COUNT, MICROBIAL; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VANCOMYCIN RESISTANCE;

EID: 60249090493     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.09.006     Document Type: Article

References (18)

1. Rayner C.R., Forrest A., Meagher A.K., Birmingham M.C., and Schentag J.J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42 (2003) 1411-1423
2. Adembri C., Fallani S., Cassetta M.I., Arrigucci S., Ottaviano A., Pecile P., et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 31 (2008) 122-129
3. Allen G.P., Cha R., and Rybak M.J. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 46 (2002) 2606-2612
4. Cha R., Brown W.J., and Rybak M.J. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 47 (2003) 3960-3963
5. LaPlante K.L., and Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48 (2004) 4665-4672
6. Huang V., and Rybak M.J. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother 49 (2005) 302-308
7. Zinner S.H., Gilbert D., Lubenko I.Y., Greer K., and Firsov A.A. Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. J Antimicrob Chemother 61 (2008) 629-635
8. Stalker D.J., and Jungbluth G.L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42 (2003) 1129-1140
9. MacGowan A.P. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 51 Suppl. 2 (2003) ii17-ii25
10. Meagher A.K., Forrest A., Rayner C.R., Birmingham M.C., and Schentag J.J. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 47 (2003) 548-553
11. Jones R.N., Ross J.E., Fritsche T.R., and Sader H.S. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 57 (2006) 279-287
12. Firsov A.A., Shevchenko A.A., Vostrov S.N., and Zinner S.H. Inter- and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 42 (1998) 659-665
13. Firsov A.A., Chernykh V.M., and Navashin S.M. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob Agents Chemother 34 (1990) 1312-1317
14. Firsov A.A., Lubenko I.Y., Smirnova M.V., Strukova E.N., and Zinner S.H. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother 52 (2008) 1924-1928
15. Firsov A.A., Savarino D., Ruble M., Gilbert D., Manzano B., Medeiros A.A., et al. Predictors of effect of ampicillin-sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother 40 (1996) 734-738
16. Firsov A.A., Zinner S.H., and Lubenko I.Y. In vitro dynamic models as tools to predict antibiotic pharmacodynamics. In: Nightingale C.H., Ambrose P.G., Drusano G.L., and Murakawa T. (Eds). Antimicrobial pharmacodynamics in theory and clinical practice. 2nd ed. (2007), Informa Healthcare USA, Inc., New York, NY 45-78
17. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
18. Firsov A.A., Lubenko I.Y., Vostrov S.N., Portnoy Y.A., and Zinner S.H. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob Agents Chemother 49 (2005) 2642-2647